Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Thiamine deficiency aggravates experimental colitis in mice by promoting glycolytic reprogramming in macrophages
Publication Year: 2025 Source: Br J Pharmacol PMID: 39890689 DOI: 10.1111/bph.17435
BACKGROUND AND PURPOSE: Inflammatory bowel disease (IBD) is closely associated with immune dysfunction, where nutrient-mediated metabolic flux dictates immune cell fate and function. Thiamine is a central water-soluble vitamin involved in cellular energy metabolism, and its deficiency has been reported in IBD patients. However, whether thiamine deficiency is a cause …
Understanding the therapeutic toolkit for inflammatory bowel disease
Publication Year: 2025 Source: Nat Rev Gastroenterol Hepatol PMID: 39891014 DOI: 10.1038/s41575-024-01035-7
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a group of chronic, immune-mediated disorders of the gastrointestinal tract that present substantial clinical challenges owing to their complex pathophysiology and tendency to relapse. A treat-to-target approach is recommended, involving iterative treatment adjustments to achieve clinical response, reduce inflammatory …
Quantitative proteomic studies of the intestinal mucosa provide new insights into the molecular mechanism of ulcerative colitis
Publication Year: 2025 Source: BMC Gastroenterol PMID: 39891110
BACKGROUND: Differentiation between ulcerative colitis (UC) and other intestinal inflammatory diseases is difficult, and the precise etiology of UC is poorly understood. Thus, there is a need for novel diagnostic and prognostic biomarkers for UC. METHODS: Intestinal mucosal biopsy tissue specimens of inflamed (ulcerative colitis-inflamed, UC-I) and non-inflamed (ulcerative colitis-noninflamed, …
Real-world of Limosilactobacillus reuteri in mitigation of acute experimental colitis
Publication Year: 2025 Source: J Nanobiotechnology PMID: 39891249
Probiotics have been proposed as a potential strategy for managing ulcerative colitis (UC). However, the underlying mechanisms mediating microbiota-host crosstalk remain largely elusive. Here, we report that Limosilactobacillus reuteri (L. reuteri), as a probiotic, secretes cytoplasmic membrane vesicles (CMVs) that communicate with host cells, alter host physiology, and alleviate dextran …
Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab
Publication Year: 2025 Source: Aliment Pharmacol Ther PMID: 39891357
No Abstract
A qualitative exploration into the lived experiences of females with a gastrointestinal condition
Publication Year: 2025 Source: J Health Psychol PMID: 39891424 DOI: 10.1177/13591053251315685
Research typically addresses the experiences of those with gastrointestinal (GI) conditions using quantitative methods, even though qualitative exploration of lived experiences could provide valuable knowledge for health and policy stakeholders. The study explored the lived experiences of eight females with irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) using …
Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis-A Safety Analysis
Publication Year: 2025 Source: United European Gastroenterol J PMID: 39891572
BACKGROUND: Etrasimod is an oral, once-daily (q.d.), selective sphingosine 1-phosphate (S1P)(1,4,5) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO). Coadministration of drugs that inhibit MAO with opioids …
The power of real-world data: insights into incident IBD populations in the modern era
Publication Year: 2025 Source: J Crohns Colitis PMID: 39891575 DOI: 10.1093/ecco-jcc/jjaf013
No Abstract
Decoding the proteomic landscape of inflammatory bowel disease
Publication Year: 2025 Source: J Crohns Colitis PMID: 39891576
No Abstract
Screening for Spondyloarthritis in Patients with Inflammatory Bowel Disease - SPARTAN 2024 Annual Meeting Proceedings
Publication Year: 2025 Source: Curr Rheumatol Rep PMID: 39891807 DOI: 10.1007/s11926-025-01181-0
PURPOSE OF REVIEW: There is an unmet need to adequately identify, describe and treat the musculoskeletal manifestations of patients with inflammatory bowel disease (IBD). At the 2024 SPARTAN annual meeting, we reviewed the current literature on the prevalence and presentation of spondyloarthritis in patients with IBD and discussed screening strategies …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide